This 2019 systematic review evaluated 13 studies involving 754 patients with muscle-invasive bladder cancer (MIBC) who received neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) prior to radical cystectomy. The analysis demonstrated a complete pathological response (pT0) in 30% of patients and pathological downstaging to non–muscle-invasive disease (
